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Diabetes Mellitus: Concerns, Treatment Options, and the Future
By: Ryan Curry

Diabetes Mellitus 2
Introduction:
According to the Center of Disease Control (CDC), twenty-nine million people in the
United States were said to have diabetes in 2014. This equates to one out of every eleven
individuals having diabetes. Consequently, one out of every four people do not know they have
diabetes (CDC 2014). A study conducted by David Nathan, professor of medicine at Massachusetts
General Hospital, mentions that “more than 80 million people are considered to be at high risk of
developing it [diabetes]. Worldwide, more than 350 million people are estimated to have type two
diabetes” (Nathan 2015). Diabetes has been an epidemic that has been present worldwide for many
years. The amount of people that are being diagnosed with diabetes, especially type two diabetes,
has drastically increased in recent years. According to an article released by the Huffington Post
in 2013, 382 million people in the world were living with diabetes. The article also goes on to say
that approximately forty-six percent of the population is undiagnosed. Comparing the amount of
people that were said to have diabetes in 2014 and the amount of people estimated to have cancer
of any type in 2013 is eye-opening. According to the National Cancer Institute, “In 2013, there
were an estimated 14,140,354 people living with cancer of any site in the United States” (Cancer
Stats Facts). According to a study conducted by Javier Escalada, an affiliate of the University of
Narvarra, in Pamplona, Spain, “Diabetes is currently among the top five causes of death in most
high-income countries and resulted in 4.6 million deaths globally in 2011. The prevalence of
diabetes, particularly type two (T2DM), continues to grow at an unprecedented rate. In 2011, 360
million persons had diabetes, of which 95% have T2DM. In 2030, there will be approximately 552
million people with diabetes” (2016). A quick Google search with the term ‘diabetes’ results in
262,000,000 different sites or articles that pertain to diabetes. Diabetes is a disease that many
people know about generally speaking, but the details are unknown to most people. The cost

Diabetes Mellitus 3
associated with having diabetes is another reason why it is of much concern. An article written by
the Huffington Post in 2013 says that the world spent 548 billion dollars on diabetes health care - 11 percent of the total spent for health care worldwide. In the United States alone, 245 billion
dollars were spent on diabetes during that year. After adjusting for population, age and sex
differences, average medical expenditures among people with diagnosed diabetes were 2.3 times
higher than what expenditures would be in the absence of diabetes. The article also states that, if
diabetes continues to increase at the rate it is, by 2035 the percentage of people with diabetes will
increase by 55% (2013). These very overwhelming and serious statistics show the necessity of a
close review of type two diabetes and where future research is going. This review intends to
investigate diabetes through its history, the genetics behind the disease, the physiology of insulin
in the body, the different treatment options for diabetes, the monetary concerns, and by an analysis
of the future, to shed light on how diabetes is a very serious disease that needs to be on the forefront
of medicine.
What is Diabetes?:
Diabetes is a metabolic disorder secondary to a deficiency of insulin secretion or insulin
resistance. This accounts for type one and type two diabetes, respectively. Common symptoms
that people experience with diabetes are polyuria (increased urination), polydipsia (increased
thirst), and weight loss (Papadakis 2016). The pancreas, the organ that produces insulin, facilitates
the regulation of blood sugar. Type one diabetics do not have sufficient secretion of insulin because
of a mutation of the pancreatic genes (Bratman 2007). Type two diabetics have a resistance to
insulin. Their bodies still produce insulin, but not at as quick of a rate, and their bodies are not as
receptive to the hormone (American Diabetes Association). Diabetes, if left untreated, “results in
relatively specific long-term complications affecting the eyes, kidneys, and peripheral and
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autonomic nervous systems, accounting for more adult cases of vision loss, end-stage kidney
disease, and amputation than any other disease” (Nathan 2015). Diabetes is a disease that
becoming an epidemic. Public health officials are labeling this as a crisis because of the severity
of the disease if left untreated.
History:
The history of diabetes is extensive, which is well documented by the American Diabetes
Association. The history of diabetes dates back to 1425 when it was first seen in the English
language. The next mention of diabetes following its start in 1425, was in 1910 when an English
physiologist named Sir Edward Sharpey-Schafer coined the term insulin following a study he
conducted on the pancreas. The term insulin comes from the Latin “insula”, which means island.
This referenced the insulin-producing islets of Langerhans in the pancreas. A few years later, in
1915, the only treatment option for treating diabetes was released: severe calorie restrictions.
Scientists knew that there was a lack of insulin production, but it was unknown how to give people
with diabetes the necessary insulin to counteract hyperglycemic episodes. A year later, The
Treatment of Diabetes Mellitus was published by Elliot Joslin, MD, a clinician and an educator
that is known as one of the most influential voices in diabetes care. In 1921, Frederick Banting,
MD, along with a student assistant, Charles Best, MD, extracted insulin from the pancreas of a
dog. They then injected the insulin into dogs whose pancreases had been removed and saw that
the dogs’ blood glucose levels decreased. This prompted the purification of insulin so that it could
be used in humans, done by James Collip, department chair of biochemistry at McGill University.
In 1922, a year after it was discovered that insulin lowers blood glucose levels, insulin was injected
for the first time into a human. Diabetic teenager Leonard Thompson was the individual that
received the injection. He improved dramatically, supporting the claim that insulin lowers blood
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glucose levels. With this supported evidence, the commercial production of insulin began in 1923
by Eli Lilly and Company. In 1936, the mechanism to prolong insulin effects was discovered by
Novo Nordisk owner Hans Hagedorn. By adding protamine to the insulin, the effects were
lengthened. The lengthened effects of insulin is what diabetics are treated with to manage everyday diabetes regulation (American Diabetes Association).

Thirty years after the term insulin was coined, the American Diabetes Association was
founded because of the increasing incidence of diabetes and the complications developed from the
disease. A year after the creation of the American Diabetes Association, the first scientific session
on diabetes was held in Cleveland, Ohio. This session, now an annual meeting, began the research
process for diabetes. In 1946, the National School Lunch Act was signed by President Truman.
This act improved nutrition standards, ensuring healthy meals and snacks in schools. This act was
intended for more than just diabetes prevention. There were multiple uses and functions of the act,
but it is greatly applicable to the history and progression of diabetes management and treatment.
Three years following the enactment of the School Lunch Act, the mechanism of insulin was
discovered by Dr. Rachmiel Levine. He discovered that insulin “works like a key”. What he meant
by this was that insulin opens the door to transport glucose into cells. His discovery eventually led
to new medications that treat type two diabetes. With more and more knowledge being obtained
about glucose consumption, the American Diabetes Association, the American Dietetic
Association, and the U.S. Public Health Service created a meal plan in 1950 that divided foods
into six groups based on the calories, carbohydrates, proteins, and fats in each serving of food.
With more research, the first oral medication became available in 1955, sulfonylureas. This
medication stimulated the pancreas to release more insulin. It was not until 1959 that the distinct
types of diabetes were identified. Drs. Berson and Yalow developed a method for measuring
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insulin in the blood. They noticed that some people with diabetes still made their own insulin, to
which the two distinct types of diabetes were formed. In 1971, researchers discovered insulin
receptors on cell membranes. This discovery supported the idea that missing or defective receptors
could prevent glucose from entering the cells, thus contributing to the insulin sensitivity of type
two diabetes. Hypoglycemia, or low blood sugar, can cause severe effects if not treated. To treat
severe hypoglycemia, Eli Lilly and Company released glucagon in 1961, a hormone produced by
the pancreas to raise glucose levels (American Diabetes Association).

It was not until 1966 that the first successful pancreas transplant was performed. This
surgery, performed at the University of Minnesota, was the first “effective” cure for diabetes.
Although there is the risk of rejection from the donor pancreas, for many people this was a way to
win the lifelong battle against diabetes. In 1978, the first medical infusion pumps were invented,
which allowed insulin to be delivered to the body without the use of a syringe. It was not for
another sixteen years that Metformin, a drug used to treat type two diabetes was introduced to the
market. Two years following the release of Metformin, Acarbose was introduced as the first alpha
glucosidase inhibitor. A study published in the New England Journal of Medicine reports that, in
2014, the incidence of diabetic complications have dramatically improved as a result of research
advances and preventative care of the course of 20 years. The study showed a 52.9% reduction in
stroke; 67.8% reduction in acute myocardial infarction; 51.4% reduction in amputation; 28.3%
reduction in end stage renal disease and 64.4% reduction in hyperglycemic crisis deaths (American
Diabetes Association). The history of diabetes is extensive and it is still being added to. The history
will continue to grow until new discoveries are found, until the entire population understands the
severity of this disease, and until the countless type two diabetics start to adjust their lifestyle
choices.
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Genetics of Diabetes:

It is widely known that our genetics make up who we are as human beings. Genetics
provide the make-up for every single organism on this planet. Genetics is not widely discussed or
talked about until a disease or problem is discovered or until it worsens. This is what happened
with diabetes. People questioned how a baby just born into this world could have this disease. This
led to countless research studies about the genetics behind diabetes. A study conducted by Ewan
Pearson, from Ninewells Hospital & Medical School in the United Kingdom says that there are a
large number of causes of monogenic diabetes accounting for approximately 5% of diabetic cases
(2008). He notes that “in the last decade, there has been a great leap forward in our understanding
of genetic forms of diabetes, how genetic variation predisposes to type one and type two diabetes,
and how genetic testing can start to play a role in the outpatient management of diabetes.” Because
monogenic diabetes is so rare, there are three key reasons, according to Pearson, why it is important
to recognize and diagnose these forms of diabetes. The first reason is because diabetes is usually
inherited in a dominant Mendelian manner. This allows family members to have predictive genetic
testing allowing for early detection of diabetes. Secondly, “knowing the precise cause provides
insight into how an individual’s diabetes will progress, and what associated abnormalities should
be screened for.” The last reason is because recent work has identified how understanding the
etiology of a patient’s diabetes can impact their therapeutic management. There are, however, a
few causes due to monogenic disorders or insulin action. Some include mutations of the PPARG
and AKT2 genes. A PPARG mutation or deletion causes insulin resistance, which can affect both
type one diabetics and type two diabetics (Le et. al 2003). An AKT2 deficiency shows an “impaired
ability of insulin to lower blood glucose because of defects in the action of the hormone on liver
and skeletal muscle” (Cho et. al 2001). A vast majority of cases, however, are characterized by
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beta-cell dysfunction. A study published in the Alimentary Pharmacology and Therapeutics
Journal concludes that “Insulin resistance is almost certainly the result of a complex interaction of
environmental/acquired factors and genetic factors. Further studies are needed to elucidate the
respective role of these components in the expression of insulin resistance and type two diabetes”
(Carulli 2005).

Monogenic cases accounts for only 5% of diabetic cases. This does not account for the
95% of the population with type one or type two diabetes. Type two diabetes is said to be
multifactorial. This is because of common variations between genes, environmental factors like
obesity, and the yet undiscovered ‘viral triggers’ for type one diabetes (Pearson 2008). Up until
the early 2000s, the genetics behind diabetes was unknown. There is still a lot that is unknown
about the disease, but with the number of studies that are being conducted, researchers are
furthering the understanding behind this mysterious disease.

Physiology of Insulin in the Body:
As we eat food, our bodies break down the food into usable energy and nutrients. The
usable energy is in the form of glucose. When there is an influx of glucose in the body, the blood
glucose levels increase. According to WebMD, target blood sugar should be between 100 and 160
mg/dL (WebMD). Blood sugars that are unregulated can cause serious effects, even death. Because
of this, our bodies have a natural mechanism to counteract the elevated glucose levels. When
glucose enters the bloodstream, it comes across the beta islet cells of the pancreas. On the cell
membrane is a protein carrier channel, called GLUT 2. This channel ushers glucose into the beta
cells and creates ATP, while allowing the release of insulin into the blood stream. From there,
insulin can bind to the insulin receptors on the liver, adipocytes, and muscle tissues. This also will
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facilitate glucose absorption. An interesting thought is that once glucose enters the adipocytes, it
is transformed into triglycerides. When the body tries to break down fats, it starts with the
degradation of triglycerides. This forms fatty acids. This is a slower mechanism to obtain energy
that is needed to fuel the body because fat does not make as much ATP. People that are type two
diabetic have an insensitivity to insulin, which forces triglycerides to remain in the adipocytes.
This could be a cause for why many type two diabetics are obese (Silverthorn et. al 2013). The
mechanism for insulin secretion and glucose absorption is hindered or non-functional for diabetics.
This is problematic because the insulin, glucose mechanism is supposed to work without flaw to
ensure a proper regulation of blood glucose levels.
Treatment Options:
Because diabetes is such a serious and critical disease, many treatment options have been
developed to treat episodes of hyperglycemia or to simply manage diabetes mellitus. One drug that
is commonly used is Metformin, commonly known as Glucophage. According a study from the
Journal of Clinical Investigation, “metformin is widely used for the therapy of type two diabetes
mellitus. Metformin ameliorates hyperglycemia without stimulating insulin secretion, promoting
weight gain, or causing hypoglycemia” (Zhou 2001). Interestingly enough, the mechanism on how
metformin works is still an enigma. What is known about this drug is that it increases skeletal
myocyte glucose uptake while decreasing hepatic glucose production. However, with any drug,
there are side effects. In the case of metformin, some common side effects are nausea, vomiting,
weakness, and a metallic taste in the mouth. A more severe side effect can occur when first starting
to take the drug. If stomach issues present, it could be a sign of lactic acidosis (WebMD).
Metformin is a low-potency compound that “is used at high doses, resulting in only modest net
efficacy” (Zhou 2011). It is noted in the study performed by Zhou that membrane permeability of
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metformin is a time-dependent and slow process. In other words, a person who is battling diabetes
will not see immediate changes in their blood glucose levels. This can be problematic because if a
blood sugar is high enough, there needs to be almost immediate regulation to ensure there are no
long-lasting effects. A study on the mechanism by which metformin works found that, after three
months, the amount of glucagon in the participants’ bodies decreased by 4 ng/l. While it does
appear that the metformin is successful in lowering blood glucose levels, the lactate, or lactic acid,
levels increased from 0.93 mmol/l to 1.13 mmol/l (Hundal 2000). This increase in the lactic acid,
if not controlled over time, could cause a type two diabetic to go into a state of lactic acidosis.
According to WebMD, “very high levels of lactic acid cause a serious, sometimes life-threatening
condition called lactic acidosis. Lactic acidosis can also occur in a person who takes metformin
(Glucophage) to control diabetes” (WebMD). Metformin has many benefits in its regulation in
blood sugar. While immediate consequences for this drug may not be seen right away, blood tests
do show that, over time, this drug makes the blood slightly more acidic.
A second drug that is said to be effective is called Miglitol, or commonly known as Glyset,
which is used to treat type two diabetes. Miglitol is an oral alpha-glucosidase inhibitor. This
signifies that it prevents, or slows, the absorption of carbohydrates (i.e. sugars) into the body.
According to WebMD, some common side effects of this medication are diarrhea, gas, and
abdominal pain. It is also recommended not to use table sugar or to drink non-diet soda to relieve
symptoms of hypoglycemia because this drug delays the breakdown of table sugar (WebMD). An
evaluation conducted by Lesley J. Scott and Caroline M. Spencer notes that “Miglitol generally
had no effect on fasting serum insulin levels. There was also a trend to a decrease in bodyweight
with Miglitol treatment during the trial period” (Scott 2000). The study that was conducted used
participants that were deemed healthy during the screening process. They did see some positive
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results, but it is unsure how well the drug will function in individuals that have underlying diseases
or conditions. In the concluding statements of the evaluation, it is noted that “Miglitol is not
indicated for use in patients with diabetic ketoacidosis and is contraindicated in patients with
inflammatory bowel disease, colonic ulceration or partial intestinal obstruction, in patients
predisposed to intestinal obstruction, in individuals under the age of 18 years and in pregnant or
lactating women. Miglitol monotherapy does not induce hypoglycemia, but may potentiate the
hypoglycemic effects of other antidiabetic drugs” (2000). Miglitol is not as commonly used as
other type two diabetic medications. While it is an option, the risks seem to outweigh the benefits.
A second medication that falls in to the alpha-glucosidase inhibitors is a drug called
Acarbose, or commonly known as Precose. This oral medication is used to treat type two diabetes.
Like the other drugs mentioned, common side effects are diarrhea, gas, constipation, and
abdominal pain. Acarbose can be given to patients that are in the pre-diabetic stage, as it “is
effective in delaying or preventing the progression of prediabetes to type two diabetes mellitus”
(Hu et. al 2015). It was concluded by the authors of this study that “Acarbose displays ethnicityspecific effects. It is likely that the superior results in Eastern populations are related to the
mechanism of action of Acarbose, which inhibits glucosidase and thus delays the formation of
glucose, slowing its absorption and finally decreasing blood glucose” (2015). The reason for
Eastern populations having a better outcome with Acarbose than in Western populations is most
likely due to the food that these populations eat. Western populations eat more processed foods,
while Eastern populations eat less processed foods. This is a proposed reason for the overall effect
of this drug.
Pioglitazone, commonly known as Actos, is another medication used to treat type two
diabetes. For someone that is taking this oral medication, they might have side effects like sore
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throat, myalgia, weight gain, or tooth problems (WebMD). As of late, there have been ethical
concerns regarding this drug. A meta-analysis of randomized trials with this drug, performed by
four different researchers, prompted the question on the influence of medications of this class on
cardiovascular outcomes. A total of 19 trials enrolling 16,390 patients were analyzed. It was
gathered that 375 of 8,554 patients (4.4%) receiving this drug resulted in death, myocardial
infarction, or stroke. It was also gathered that “serious heart failure was reported in 200 (2.3%) of
the pioglitazone-treated patients and 139 (1.8%) of the control patients.” It is noted that
cardiovascular disease remains the most frequent cause of death and morbidity among patients
with diabetes mellitus. It was concluded overall that “the incidence of serious heart failure was
increased by pioglitazone, although without an associated increase in mortality” (Lincoff et. al
2007). In the same class of drug, Avandia, commonly known as Rosiglitazone, presents itself.
Avandia is a drug that is used to treat type two diabetes by increasing insulin sensitivity. It does
so by decreasing the amount of glucose released by the liver. It does not cause the body to make
more insulin, therefore, when used alone, Avandia does not cause low blood glucose (Joslin
Diabetes Center). Some common side effects of taking this oral medication are a headache and a
cough (WebMD). A meta-analysis of the use of this drug has some startling data. It was noted that
“myocardial infarctions occurred 14% more often with rosiglitazone compared with metformin…,
and 178% more often than with insulin” (Bloomgarden 2007). Bloomgarden concluded that
rosiglitazone is “associated with a significant increase in risk of myocardial infarction and of
death.” These two drugs have raised much concern over the last few years, especially Avandia.
Both of these drugs have been called into question and have been questioned on whether or not
they should be prescribed at all. It has made researchers rethink the idea of treating type two
diabetes with medications other than insulin.
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Insulin, like mentioned above, is a naturally producing hormone in the body. There is
concern ethically about using insulin as the treatment option for type two diabetes. There is concern
because some people believe that it is unethical to receive insulin that was mass produced from
human genes. The rationale behind this concern is because of the fact that the insulin that is being
produced from human genes came from embryonic stem cells. This belief that receiving insulin,
however, should be a false statement. Insulin was designed to work perfectly in our bodies. There
are insulin receptors all over our bodies to stimulate glucose uptake into cells. Insulin and glucose
are a pair that work well together. When an influx of glucose enters the body, insulin secretion
increases. When there is a small amount of glucose in the body, the amount of insulin decreases.
This, of course, is what happens in non-diabetic people. By treating hyperglycemia with its partner,
insulin, many concerns of other diabetes management drugs are alleviated. It is stated in the El
Paso Times that “insulin can help lower the chances of blood vessel problems, as well as heart
attack and stroke, by offering better glucose control” (Mier 2009). The author of this article, a
clinical instructor, states that “insulin therapy is often the best option for effective treatment of
diabetes.” This shows how people that have a medical background agree that insulin is the best
option for diabetes management.
Economics of Diabetes Treatment:
Paying for any medical concern can be a financial burden for many people. It can be even
worse depending on the type of insurance you have or if you have insurance at all. For diabetics,
the cost of insulin is becoming so expensive that people cannot afford to regulate their blood
sugars. A reason for this is because of the fact that there is not a generic form of insulin. According
to a NPR talk regarding insulin, when insulin was first mass produced, it was taken and purified
from pigs and cows. As technology advanced, researchers found ways to produce human insulin
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by placing the gene that codes for insulin in bacteria. However, instead of keeping both forms of
insulin on the market, the older method became obsolete in the United States. It eventually was
taken off the market (NPR 2015). During this NPR talk, it was said that “the drug now costs up to
$400 a month. And because of that high cost, many of the estimated 29 million Americans with
diabetes can’t afford it.” This is concerning because many more complications will be seen with
the people that are diabetic, all because they cannot afford the drug that keeps their body from
completely turning on them. For the Eli Lilly Company, “insulin was an important product for
[them], one of the world’s largest pharmaceutical manufacturers with sales of over $5 billion”
(Christensen 2004). It was suggested from this report that people that live with diabetes spend
“$10,000 per year.” This accounts for insulin, syringes, blood glucose testing equipment,
complications, and doctors’ visits. According to Exhibit 4 from the report by Christensen, in 1994,
the Eli Lilly Company profited $456 million dollars in North America alone. The next closest
competitor was the Novo-Nordisk company, profiting $132 million. This shows how insulin can
be so expensive in the United States. There is one dominant company that controls the prices of
insulin. The Eli Lilly Company is using the method of the human insulin gene being placed in
bacteria to mass produce. They are no longer utilizing the cow and pig method. This is problematic
because the amount of people with diabetes is increasing and the cost for everyday life is increasing
as well. With this being said, it is becoming increasingly harder for people to pay for treatment for
their diabetes.
A Day in the Life of a Diabetic:
Providing the facts and treatment options that are currently available for diabetes helps
show the severity of the disease. But this does not show how the people and their family members
are affected by the disease. For me personally, I have a cousin that was diagnosed with type one
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diabetes at a very young age. At the time, she was too young to understand what exactly was going
on. After almost thirteen years of living with diabetes, she has come to understand what diabetes
actually is. To help capture the day in the life of a diabetic, I interviewed my aunt. My aunt notes
that my cousin was hospitalized for three days after being diagnosed with diabetes. After those
three days, they were expected to take my cousin home and treat this disease. For many people,
when a loved one is diagnosed with diabetes, especially type one, it is usually the first occurrence
of it in the family. According to my aunt, “There is never a moment or a break where I don’t have
to think about diabetes.” She goes on to say, “Diabetes is the last thing I think about before going
to bed and the first thing I think about when I wake up.” For my cousin, the start of treating her
diabetes for the day starts at 7:30 in the morning. From that point on, her blood glucose is checked
every 2 ½- 3 hours. As my cousin grew up, she began going to school. For a diabetic, your daily
school routine is much different from those that are not diabetic. During the middle of the day, my
cousin has to leave class for a snack, check her blood sugar in the nurse’s office before lunch, gym,
and before leaving school to come home. If she happens to have an episode of hypoglycemia or
hyperglycemia, she may be unable to concentrate or participate in school activities. Once home,
her blood sugar is checked before dinner, before her snack at 8:00 PM, and right before she goes
to bed. My cousin has been fortunate enough to have very caring parents and siblings that help her
manage her diabetes. However, my cousin is at the start of her teenage years, and, with that, comes
a lot of hormonal changes. Natural hormonal changes in the body can cause drastic changes in
blood sugar levels, even for non-diabetic people. So, for diabetics, diabetes management is even
more crucial during the teenage years. My cousin has a diabetic pump, which allows insulin to be
given without injections multiple times a day. While this pump has alleviated a lot of pain and
stress, it can still be problematic. It is very easy for the tube connecting the pump to the body to
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clog, thus causing hyperglycemia. And while the pump lessens the amount of daily injections, the
pump needs to be changed out every 2-3 days. My aunt concluded that she would take the diabetes
away from my cousin if she could. Diabetes care and management is a strategy game, and without
a support system around you, diabetes is a very difficult disease to treat for (L. Palese, personal
communication with author, January 29, 2017).
Future Innovations:
Diabetes regulation via medication is not the favored method. Physicians would prefer that
type two diabetics change their lifestyles and eventually wean off the prescribed medications.
However, type one diabetics do not have this luxury. Because physicians know that the acquisition
of type one diabetes is genetically based, other treatment options have been developed. According
to Rebecca Boyle, writer for Popular Science, “researchers at the Mayo Clinic are developing an
artificial pancreas that accounts for slight, low-intensity physical activities that can impact blood
sugar levels. The researchers are developing a closed-loop system that includes a glucose monitor,
automatic insulin pump, activity monitors that attach to the body and a central computer that uses
an insulin-delivery algorithm to determine how much of the hormone to dispense” (Boyle 2011).
A study conducted on the concept of an artificial pancreas was tested on one-hundred virtual
patients. It was concluded that the Model Predictive Control (MPC) is one of the most commonly
used methods for the AP [artificial pancreas]. The main advantage of MPC is the ability to handle
hard constraints on input variables and soft constraints on output variables in systematic ways.
This method reduces the time spent in hypoglycemic states and also hyperglycemic states (Boiroux
et. al 2017). Many different methods are being explored as to the best method for the artificial
pancreas. As it stands right now, it is a combination of advances that have been made in the diabetic
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field. There is more research and trials to be performed, but each day is one step closer to perfecting
this new discovery.
Stem cell research has, as of late, been a controversial and ethical conversation in the
United States media. This type of research is controversial because of the need to take nondifferentiated embryonic stem cells to make the beta cells that produce insulin. An article written
in National Geographic states that father, and now stem cell researcher at Harvard, Doug Melton,
“has created virtually an unlimited supply of the cells that are missing in people with type one
diabetes” (Weintraub 2014). The technique developed by Melton also works using stem cells that
don’t require destroying an embryo. This voids the controversial and ethical concerns. He notes
that induced pluripotent stem cells are a possible option. A study published in the Journal of
Pharmacological Sciences concludes that “we [the researchers] have managed to produce insulin
secreting PE [pancreatic endoderm] from hESCs. These hESC-derived PE were then transplanted
into pregnant female diabetic mice, where they significantly alleviated diabetes mellitus symptoms
including hyperglycemia and hyperinsulimenia (Xing et. al 2016). This study shows the promise
that stem cell research has in the diabetic field. While there are ethical concerns about taking
embryonic stem cells, it is possible to take stem cells from adults and induce the pluripotent cells
to create the necessary beta cells that are deficient in all diabetics to produce the insulin necessary
to regulate blood sugars. With more research, it is obvious that great strides in the diabetic
community will be made.
Prevention is Possible with Diabetic Resources:
Living with untreated diabetes is difficult. Type two diabetes, however, can be avoided.
Someone with type two diabetes can decide at any moment that they want to change their lifestyle
so that they may cure themselves from diabetes. Going about this alone can be difficult. However,
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there are plenty of resources that are available for type two diabetics to start living healthier lives.
A few very credible sources to find ways to live healthier with diabetes is through the American
Association of Diabetes Educators. On their website, they offer programs, lifestyle tips, and ways
to get in touch with a diabetes educator. Another credible source for people wanting to begin the
fight against diabetes is through the National Institute of Diabetes and Digestive and Kidney
Diseases. On their website, they offer ways to live with diabetes so that it is controlled. For some
people, the first step to ridding themselves of the disease is to get it under control. The Centers for
Disease Control and Prevention offer resources on the most current diabetes treatment options, the
basics about diabetes, and also programs and initiatives. The American Diabetes Association offers
resources about the basics behind diabetes, living with diabetes information, and information on
food and fitness. On all of these websites, ways to eat healthier, some with recipes, are available.
Additionally, the National Football League has accepted the challenge to fighting childhood
obesity. Type two diabetes has changed in recent years from the initial beliefs of type two diabetes
being adult onset. Now, type two diabetes is being seen and diagnosed at any age. The NFL Play
60 program encourages children to exercise for at least an hour a day, whether it be walking,
playing sports, or even dancing. Childhood obesity is one of the greatest causes of type two
diabetes in today’s society. The amount of children in the United States that are considered obese
is frightening. These organizations realize how important it is to treat diabetes. Diabetic
researchers and educators can only do so much when it comes to diabetes. The individual that is
struggling with type two diabetes needs to make lifestyle choices that will better themselves so
that they can rid themselves of type two diabetes.
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Conclusion:
Diabetes has been around since at least 1425. Its extensive history shows how prevalent
diabetes is and how it is something that people need to take more seriously. Diabetes, as a whole,
is amongst the top five causes of death worldwide. People’s lives can be drastically changed or
ended if their diabetes goes undiagnosed or untreated. Type two diabetes is by far the most
common type of diabetes and is a disease that can be completely avoided. With changes in lifestyle,
dietary habits, and exercise patterns, people with type two diabetes can fight this disease. With
diabetes being an epidemic throughout the world, many treatment methods have been developed.
Though type two medications have been helpful, the most helpful treatment option is insulin. The
naturally occurring hormone in our bodies is the best soldier in the fight against diabetes. Human
physiological mechanisms respond effectively and efficiently to insulin, a natural product of the
body. There have been many improvements for alternative treatments. For type one and possibly
type two diabetics, the concept of having a computerized “pancreas” can alleviate much of the
concerns and worries. Stem cell research can take our pluripotent cells and create beta cells that
produce insulin. The great strides that have been taken in the fight against diabetes have helped
tremendously, but the world will not be able to rid itself of diabetes unless the entire population
wholeheartedly believes they can and begins to also hold up their part in eradicating this disease?
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